Anti-CD19/CD22 CAR-T cell therapy (The First Affiliated Hospital Of Soochow University)

N/A

Report date: 2023/10/13 11:52:07

Base Information

Drug NameAnti-CD19/CD22 CAR-T cell therapy (The First Affiliated Hospital Of Soochow University)
Drug Alias NameCD22/CD19 CAR T(The First Affiliated Hospital Of Soochow University)CD19CD22 CAR-T Therapy(The First Affiliated Hospital Of Soochow University)CD19CD22 CAR-T cells Therapy(The First Affiliated Hospital Of Soochow University)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19Anti-CD22
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsLymphomaPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesThe First Affiliated Hospital Of Soochow University
China Registration ClassN/A

Develop Information

Active CompaniesThe First Medical Center of Chinese PLA General HospitalThe First Affiliated Hospital Of Soochow University
Inactive CompaniesN/A
Active IndicationsLymphomaPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A